Premium
Pharmacogenetic evaluation of a DISP1 gene variant in antidepressant treatment of obsessive–compulsive disorder
Author(s) -
Lisoway Amanda J.,
Zai Gwyneth,
Tiwari Arun K.,
Zai Clement C.,
Wigg Karen,
Goncalves Vanessa,
Zhang Danning,
Freeman Natalie,
Müller Daniel J.,
Kennedy James L.,
Richter Margaret A.
Publication year - 2018
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.2659
Subject(s) - paroxetine , fluvoxamine , genome wide association study , sertraline , antidepressant , pharmacogenetics , citalopram , serotonin reuptake inhibitor , fluoxetine , psychiatry , single nucleotide polymorphism , psychology , genetic association , medicine , oncology , clinical psychology , genotype , genetics , anxiety , gene , biology , serotonin , receptor
Objectives A recent genome‐wide association study (GWAS) in obsessive–compulsive disorder (OCD) reported a significant marker in the dispatched homolog 1 (Drosophila) gene ( DISP1 gene) associated with serotonin reuptake inhibitor (SRI) antidepressant response (Qin et al., [Qin, H., 2015]). DISP1 has never been examined before in terms of association with SRI response until this GWAS. We attempt to replicate the GWAS finding by investigating the association of the DISP1 rs17162912 polymorphism with SRI response in our sample of 112 European Caucasian OCD patients. Methods Patients were previously treated naturalistically with up to 6 different SRIs sequentially, including 5 selective SRIs (fluoxetine, fluvoxamine, sertraline, paroxetine, and citalopram) and 1 SRI (clomipramine). Each medication trial was evaluated retrospectively for response and was rated categorically as either responder or nonresponder using the Clinical Global Impression–Improvement scale. Fisher's exact test was used to investigate the relationship between the DISP1 rs17162912 genotype distribution and SRI response. Results We did not observe a significant association between rs17162912 and SRI response ( p = .32). Conclusion This replication study did not support the role of DISP1 in predicting SRI response in OCD; however, methodological differences between the original GWAS and our study, as well as limited power and low minor allele frequency, may have hindered replication.